Terminated NA INTERVENTIONAL 1-arm NCT01012440

Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

Role of PEM Flex Solo II PET Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

Sponsor: University of Chicago

Interventions MRI scan PEM Flex Solo II PET Scanner

Updated 6 times since 2017 Last updated: Jun 29, 2015 Started: Nov 30, 2009 Primary completion: May 31, 2011 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Poor accrual

Other terminated trials from University of Chicago

See all terminations from University of Chicago

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

This NA trial investigates Breast Cancer and is currently terminated or withdrawn. University of Chicago leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2021 — Jul 2024 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA
Feb 2017 — Jun 2018 [monthly]

Terminated NA

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Chicago

Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States